Results 201 to 210 of about 333,981 (315)

The Multifaceted Role of Androgen Receptor Signaling in Immunity: Implications for Oncology. [PDF]

Mol Cancer Res
Lee P, Nelson PS.
europepmc   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Preventing Atherosclerotic Cardiovascular Disease in Young Male Androgen Abusers. [PDF]

Clin Cardiol
Bond P, Smit DL, Verdegaal T, de Ronde W.   +3 more
europepmc   +1 more source

One‐year follow‐up after fractionated ultra‐high‐dose‐rate FLASH radiotherapy in patient with extramammary Paget disease of the scrotum

Precision Radiation Oncology, EarlyView.
An elderly male patient with extramammary Paget disease of the scrotum and multiple metastases was treated with fractionated FLASH‐RT (40 Gy in 5 fractions) in the scrotal lesion. Abstract Objective Ultrahigh‐dose‐rate radiotherapy (FLASH‐RT) has been shown to reduce radiation‐induced normal tissue injury in preclinical studies.
Hui Luo, Chengliang Yang, Ronghu Mao, Leijie Ma, Hongchang Lei, Peng Chen, Yanping Zhang, Meng Xu, Chao Wang, Yiwu Wang, Mingxia Wu, Chanjun Sun, Han Liu, Hui Liu, Hong Ge   +14 more
wiley   +1 more source

Muscle pain in a woman with congenital adrenal hyperplasia due to 21-hydroxylase deficiency resolved with testosterone therapy. A case report with 10 years of follow-up. [PDF]

Front Endocrinol (Lausanne)
Hubska J, Jaszczuk P, Betlejewska J, Bylińska N, Bobrowicz M, Rak-Makowska B, Ambroziak U.   +6 more
europepmc   +1 more source

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background The management of intermediate‐risk early prostate cancer (PCa) is challenging due to the difficulty in distinguishing indolent from aggressive tumors. This study explores the association between genomic alterations and the tumor and its microenvironment (TME) and implications for disease progression. Methods We performed multi‐omic
William Lautert‐Dutra, Camila M. Melo, Luiz P. Chaves, Francisco C. Souza, Vida Talebian, Cheryl Crozier, Mary Anne Quintayo, Linda Liao, Dan Dion, Fabiano P. Saggioro, Felipe S. Avante, Rodolfo B. dos Reis, Jeremy A. Squire, Jane Bayani   +13 more
wiley   +1 more source

Intermittent Fasting and Androgen Receptor Signaling in Prostate Cancer: Metabolic Crosstalk and Therapeutic Implications. [PDF]

Int J Mol Sci
Gromadzka G, Bendykowska M.
europepmc   +1 more source

Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis

The Prostate, EarlyView.
ABSTRACT Background As overall survival improves in metastatic hormone‐sensitive prostate cancer (mHSPC), non‐cancer causes of death are increasingly relevant. Methods We conducted a real‐world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration‐resistant prostate
Marta Garcia de Herreros, Clara Rodrigo, Laura Ferrer‐Mileo, Laia Fernández‐Mañas, Joel Mases, Nely Diaz, Antoni Vilaseca, Mariana Altamirano, Roser Gibanel, Maria José Ribal, Natalia Jimenez, Oscar Reig, Mariona Figols, Miguel Ángel Climent, Albert Font, Begoña Mellado   +15 more
wiley   +1 more source

Regulatory risk loci link disrupted androgen response to the pathophysiology of polycystic ovary syndrome. [PDF]

J Endocr Soc
Srivastava J, Ovcharenko I.
europepmc   +1 more source

Castration Resistance Accelerates Prostate Cancer Kinetics

The Prostate, EarlyView.
ABSTRACT Background Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide efforts to determine optimal timing of therapy initiation.
Sheila Jonnatan, Luka Cavka, Angelo M. De Marzo, Samuel R. Denmeade, Mark C. Markowski, Emmanuel S. Antonarakis, Bruce J. Trock, Catherine H. Marshall, Ravi A. Madan, David J. Einstein, Laura A. Sena   +10 more
wiley   +1 more source